EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSSTOG00000003673
Gene Symbol: PSMD12
4 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSSTOG00000015055
Gene Symbol: PSMD13
4 Cross references
218 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSSTOG00000014883
Gene Symbol: PSMD14
4 Cross references
211 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 3

Ensembl ID : ENSSTOG00000021411
Gene Symbol: PSMD3
3 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSSTOG00000012571
Gene Symbol: PSMD6
3 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSSTOG00000013123
Gene Symbol: PSMD7
4 Cross references
238 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSSTOG00000014464
Gene Symbol: PSMD8
3 Cross references
178 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSSTOG00000007142
Gene Symbol: PSMB11
3 Cross references
227 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSSTOG00000010374
Gene Symbol: PRMT5
4 Cross references
198 Possible Orthologues:

Protein Kinase C Alpha

Ensembl ID : ENSSTOG00000003118
Gene Symbol: PRKCA
2 Cross references
289 Possible Orthologues:

Protein Kinase C Beta

Ensembl ID : ENSSTOG00000012429
Gene Symbol: PRKCB
3 Cross references
284 Possible Orthologues:

Protein Kinase C Delta

Ensembl ID : ENSSTOG00000004583
Gene Symbol: PRKCD
4 Cross references
280 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).